Endocrine Society Endorses Bipartisan Insulin Affordability Bill

25 Mar 20264 min read0 views

GIST

INSULIN Act would expand insulin co-pay cap to commercial market and encourage competition . The Endocrine Society today endorsed the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act, a bipartisan bill to address insulin affordability introduced by Sens.

Jeanne Shaheen (D-NH), Susan Collins (R-ME), Raphael Warnock (D-GA), and John Kennedy (R-LA). This historic legislation would cap out-of-pocket insulin costs at $35 per month for people on private insurance, protecting access to this life-saving medication for millions of people with diabetes.

The legislation also would create a program to provide insulin to the uninsured. The INSULIN Act expands the $35 cap on out-of-pocket costs of insulin currently available for Medicare beneficiaries, extending the cap for those with private insurance, and addresses the underlying problems in the insulin market that contribute to escalating prices.

The bill also includes provisions ensuring that patients are receiving any insulin rebates and discounts that are normally collected by Pharmacy Benefit Managers (PBMs), and a provision to encourage more competition for generic and biosimilar insulins.

Clinical Editorial

Strategic framing of an affordability initiative

The endorsed bill is called the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act, introduced by four senators from both parties.

The Endocrine Society publicly endorses a bipartisan legislative solution aimed at reducing out-of-pocket insulin costs and expanding access for people with diabetes.

Study design and policy architecture

It outlines the bill’s core mechanisms intended to modify insurer and payer behaviors and to foster market competition, with an emphasis on patient cost-sharing limits and expanded coverage.

Additional elements address rebate flows, PBM practices, and competitive dynamics for generic and biosimilar insulins.

The content presents a legislative proposal rather than a primary research study.
Central policy levers include extending a $35 monthly cap on insulin out-of-pocket costs from Medicare to commercial plans, and introducing a program targeted at uninsured individuals.
The Society notes alignment with its own Insulin Access and Affordability Position Statement, which advocates rebate reform and a $35 monthly cap as part of improving pricing and patient access.

Population, exposure, and scope

It explicitly recognizes types 1 and type 2 diabetes, noting reliance on insulin among many individuals with diabetes.

The initiative concerns people with diabetes in the United States, including those on private insurance and those who are uninsured.
The outreach includes both insured populations (private plans) and uninsured individuals, with provisions to create outreach and support structures for the latter group.

Policy specifics and proposed operational mechanisms

Cost-sharing provisions: Plans with group or individual coverage would be required to waive deductibles and cap monthly insulin cost-sharing at $35, or limit to 25% of the list price, for at least one insulin type and dosage form.
Rebate and discount transparency: The bill would mandate Pharmacy Benefit Managers (PBMs) to pass through 100% of insulin rebates and other discounts to insurance plan sponsors, enabling patient-level benefit from savings.
Market competition: Provisions aim to stimulate competition by encouraging the entry and use of generic and biosimilar insulin products.
Uninsured support structures: A competitive grant program would fund ten states to identify uninsured people with diabetes and provide access to insulin through state programs.
Consumer resources: An insulin resource center and hotline would be established to connect uninsured individuals with resources and programs to obtain insulin.

Context and supporting rationale

The rhetoric emphasizes life-sustaining needs for insulin and references CDC estimates of diabetes prevalence in the population.

The proposal is framed within the broader context of insulin affordability as a critical, life-related issue for millions of people with diabetes in the U.S.
The text notes historical data on cost barriers, including substantial self-reported rationing of insulin among adults with diabetes in prior years.

Outcomes and evidentiary considerations

The source does not present empirical study results, clinical outcomes, or numerical analyses beyond bill-level provisions and stated goals.
There is no comparative effectiveness data or real-world outcome metrics reported within the content provided.

Limitations and uncertainties

The content does not include legislative text granularities beyond the major policy levers, so specific implementation details, funding mechanisms, timelines, and oversight structures remain undefined in the source.
It is unclear from the provided material which stakeholders besides the Endocrine Society and the sponsoring senators will be involved in execution, nor how success would be measured beyond the stated intent to expand access and reduce costs.

Relevance to clinical practice and ongoing discourse

The Endocrine Society presents endorsement as part of its policy stance on insulin access and affordability, positioning the INSULIN Act as a practical approach to address price-related barriers that affect medication adherence and life-sustaining treatment.
The statement signals ongoing collaboration aspirations with Congress to advance legislation within the current year, reflecting a preference for policy-driven change alongside clinical considerations.